A snapshot of head and neck cancer. 2015. http://www.cancer.gov/research/progress/snapshots/headandneck.
Reyes-Gibby CC, Anderson KO, Merriman KW, Todd KH, Shete SS, Hanna EY. Survival patterns in squamous cell carcinoma of the head and neck: pain as an independent prognostic factor for survival. J Pain. 2014;15:1015–22.
Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48:1232–9.
Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008;83:559–66.
Droney JM, Gretton SK, Sato H, Ross JR, Branford R, Welsh KI, et al. Analgesia and central side-effects: two separate dimensions of morphine response. Br J Clin Pharmacol. 2013;75:1340–50.
Ochroch EA, Vachani A, Gottschalk A, Kanetsky PA. Natural variation in the mu-opioid gene OPRM1 predicts increased pain on third day after thoracotomy. Clin J Pain. 2012;28:747–54.
Hickey OT, Nugent NF, Burke SM, Hafeez P, Mudrakouski AL, Shorten GD. Persistent pain after mastectomy with reconstruction. J Clin Anesth. 2011;23:482–8.
Fernandez-de-las-Penas C, Fernandez-Lao C, Cantarero-Villanueva I, Ambite-Quesada S, Rivas-Martinez I, del Moral-Avila R, et al. Catechol-O-methyltransferase genotype (Val158met) modulates cancer-related fatigue and pain sensitivity in breast cancer survivors. Breast Cancer Res Treat. 2012;133:405–12.
Reyes-Gibby CC, Spitz M, Wu X, Merriman K, Etzel C, Bruera E, et al. Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-alpha-308 G/A IL6-174G/C and IL8-251 T/A. Cancer Epidemiol Biomarkers Prev. 2007;16:2745–51.
Reyes-Gibby CC, El Osta B, Spitz MR, Parsons H, Kurzrock R, Wu X, et al. The influence of tumor necrosis factor-alpha −308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care. Cancer Epidemiol Biomarkers Prev. 2008;17:3262–7.
Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain. 2009;10:1146–50.
Reyes-Gibby CC, Shete S, Yennurajalingam S, Frazier M, Bruera E, Kurzrock R, et al. Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage. 2009;38:894–902.
Rausch SM, Clark MM, Patten C, Liu H, Felten S, Li Y, et al. Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors. Cancer. 2010;116:4103–13.
Illi J, Miaskowski C, Cooper B, Levine JD, Dunn L, West C, et al. Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. Cytokine. 2012;58:437–47.
McCann B, Miaskowski C, Koetters T, Baggott C, West C, Levine JD, et al. Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. J Pain. 2012;13:425–37.
Reyes-Gibby CC, Wang J, Spitz M, Wu X, Yennurajalingam S, Shete S. Genetic variations in interleukin-8 and interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients. J Pain Symptom Manage. 2013;46:161–72.
Stephens K, Cooper BA, West C, Paul SM, Baggott CR, Merriman JD, et al. Associations between cytokine gene variations and severe persistent breast pain in women following breast cancer surgery. J Pain. 2014;15:169–80.
Reyes-Gibby CC, Spitz MR, Yennurajalingam S, Swartz M, Gu J, Wu X, et al. Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2009;18:2636–42.
Reyes-Gibby CC, Swartz MD, Yu X, Wu X, Yennurajalingam S, Anderson KO, et al. Symptom clusters of pain, depressed mood, and fatigue in lung cancer: assessing the role of cytokine genes. Support Care Cancer. 2013;21:3117–25.
Valencia-Cruz AI, Uribe-Figueroa LI, Galindo-Murillo R, Baca-Lopez K, Gutierrez AG, Vazquez-Aguirre A, et al. Whole genome gene expression analysis reveals casiopeina-induced apoptosis pathways. PLoS One. 2013;8, e54664.
Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12:56–68.
Jeong H, Tombor B, Albert R, Oltvai ZN, Barabasi AL. The large-scale organization of metabolic networks. Nature. 2000;407:651–4.
Muurling T, Stankovic KM. Metabolomic and network analysis of pharmacotherapies for sensorineural hearing loss. Otol Neurotol. 2014;35:1–6.
Stamatiou GA, Stankovic KM. A comprehensive network and pathway analysis of human deafness genes. Otol Neurotol. 2013;34:961–70.
Reyes-Gibby CC, Yuan C, Wang J, Yeung SC, Shete S. Gene network analysis shows immune-signaling and ERK1/2 as novel genetic markers for multiple addiction phenotypes: alcohol, smoking and opioid addiction. BMC Syst Biol. 2015;9:25.
Ingenuity Pathway Analysis software. 2014. http://www.ingenuity.com/.
Kramer A, Green J, Pollard Jr J, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014;30:523–30.
Ingenuity Pathways Analysis (IPA) of Large Datasets. 2014. http://www.usc.edu/hsc/nml/assets/bioinfo/IPA/Data%20Analysis%20training%20Handouts.pdf.
IPA Network Generation Algorithm. 2014. http://www.ingenuity.com/wp-content/themes/ingenuitytheme/pdf/ipa/IPA-netgen-algorithm-whitepaper.pdf.
Calculating and Interpreting the p-values for Functions, Pathways and Lists in IPA. 2014. http://www.ingenuity.com/wp-content/themes/ingenuity-qiagen/pdf/ipa/functions-pathways-pval-whitepaper.pdf.
Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, et al. Pain measurement tools and methods in clinical research in palliative care: recommendations of an expert Working Group of the European Association of palliative care. J Pain Symptom Manage. 2002;23:239–55.
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75.
Wang K, Li M, Hakonarson H. Analysing biological pathways in genome-wide association studies. Nat Rev Genet. 2010;11:843–54.
Fridley BL, Biernacka JM. Gene set analysis of SNP data: benefits, challenges, and future directions. Eur J Hum Genet. 2011;19:837–43.
Askland K, Read C, O’Connell C, Moore JH. Ion channels and schizophrenia: a gene set-based analytic approach to GWAS data for biological hypothesis testing. Hum Genet. 2012;131:373–91.
Ersland KM, Christoforou A, Stansberg C, Espeseth T, Mattheisen M, Mattingsdal M, et al. Gene-based analysis of regionally enriched cortical genes in GWAS data sets of cognitive traits and psychiatric disorders. PLoS One. 2012;7, e31687.
Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41:899–904.
Kambur O, Kaunisto MA, Tikkanen E, Leal SM, Ripatti S, Kalso EA. Effect of catechol-o-methyltransferase-gene (COMT) variants on experimental and acute postoperative pain in 1,000 women undergoing surgery for breast cancer. Anesthesiology. 2013;119:1422–33.
Reyes-Gibby CC, Shete S, Rakvag T, Bhat SV, Skorpen F, Bruera E, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007;130:25–30.
Galvan A, Skorpen F, Klepstad P, Knudsen AK, Fladvad T, Falvella FS, et al. Multiple Loci modulate opioid therapy response for cancer pain. Clin Cancer Res. 2011;17:4581–7.
Rakvag TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain. 2005;116:73–8.
Rakvag TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain. 2008;4:64.
Uceyler N, Rogausch JP, Toyka KV, Sommer C. Differential expression of cytokines in painful and painless neuropathies. Neurology. 2007;69:42–9.
NCBI. Gene MAPK1. 2015. http://www.ncbi.nlm.nih.gov/gene/5594. Accessed Mar 2015.
Huberts DH, van der Klei IJ. Moonlighting proteins: an intriguing mode of multitasking. Biochim Biophys Acta. 2010;1803:520–5.
Hu S, Xie Z, Onishi A, Yu X, Jiang L, Lin J, et al. Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling. Cell. 2009;139:610–22.
Sun W, Quan C, Huang Y, Ji W, Yu L, Li X, et al. Constitutive ERK1/2 activation contributes to production of double minute chromosomes in tumour cells. J Pathol. 2015;235:14–24.
Slattery ML, Lundgreen A, Wolff RK. MAP kinase genes and colon and rectal cancer. Carcinogenesis. 2012;33:2398–408.
Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537–49.
Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005;15:11–8.
Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M. Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J. 2004;18:1550–2.
Liu CY, Lu ZY, Li N, Yu LH, Zhao YF, Ma B. The role of large-conductance, calcium-activated potassium channels in a rat model of trigeminal neuropathic pain. Cephalalgia. 2015;35:16–35.
Kondo T, Sakurai J, Miwa H, Noguchi K. Activation of p38 MAPK through transient receptor potential A1 in a rat model of gastric distension-induced visceral pain. Neuroreport. 2013;24:68–72.
Crown ED. The role of mitogen activated protein kinase signaling in microglia and neurons in the initiation and maintenance of chronic pain. Exp Neurol. 2012;234:330–9.
Ji RR, Gereau RWT, Malcangio M, Strichartz GR. MAP kinase and pain. Brain Res Rev. 2009;60:135–48.
Mizushima T, Obata K, Yamanaka H, Dai Y, Fukuoka T, Tokunaga A, et al. Activation of p38 MAPK in primary afferent neurons by noxious stimulation and its involvement in the development of thermal hyperalgesia. Pain. 2005;113:51–60.
Calati R, Crisafulli C, Balestri M, Serretti A, Spina E, Calabro M, et al. Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:271–8.
Zhuang ZY, Gerner P, Woolf CJ, Ji RR. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain. 2005;114:149–59.
Ma W, Quirion R. Partial sciatic nerve ligation induces increase in the phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in astrocytes in the lumbar spinal dorsal horn and the gracile nucleus. Pain. 2002;99:175–84.
Obata K, Yamanaka H, Kobayashi K, Dai Y, Mizushima T, Katsura H, et al. Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. J Neurosci. 2004;24:10211–22.
Obata K, Yamanaka H, Dai Y, Mizushima T, Fukuoka T, Tokunaga A, et al. Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats. Eur J Neurosci. 2004;20:2881–95.
Jin SX, Zhuang ZY, Woolf CJ, Ji RR. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci. 2003;23:4017–22.
Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S, Inoue K. Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia. 2004;45:89–95.
Ma W, Quirion R. The ERK/MAPK pathway, as a target for the treatment of neuropathic pain. Expert Opin Ther Targets. 2005;9:699–713.
Hurst Jr NJ, Najy AJ, Ustach CV, Movilla L, Kim HR. Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression. Biochem J. 2012;441:909–18.
NCBI. ClinVar PIK3C2G. 2015. http://www.ncbi.nlm.nih.gov/clinvar/?term=PIK3C2G%5Bgene%5D. Accessed Mar 2015.
NCBI. Gene PIK3C2G. 2015. http://www.ncbi.nlm.nih.gov/gene/5288. Accessed Mar 2015.
NCBI Gene. 2015. http://www.ncbi.nlm.nih.gov/gene/919; http://www.ncbi.nlm.nih.gov/gene/6955. Accessed Mar 2015.
VioCARTA Pathways. 2016. https://www.qiagen.com/us/shop/genes-and-pathways/pathway-details/?pwid=426. Accessed Feb 2016.
Dubois PC, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet. 2010;42:295–302.
Zhernakova A, Stahl EA, Trynka G, Raychaudhuri S, Festen EA, Franke L, et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet. 2011;7, e1002004.
Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet. 2010;42:508–14.
NCBI. Gene PDGFC. 2015. http://www.ncbi.nlm.nih.gov/gene/56034. Accessed Mar 2015.
NCBI dbSNP. 2015. http://www.ncbi.nlm.nih.gov/snp/. Accessed Mar 2015.
Pagani F, Baralle FE. Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet. 2004;5:389–96.
Choi JW, Park CS, Hwang M, Nam HY, Chang HS, Park SG, et al. A common intronic variant of CXCR3 is functionally associated with gene expression levels and the polymorphic immune cell responses to stimuli. J Allergy Clin Immunol. 2008;122(1119–1126), e1117.
Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, et al. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer. 1999;81:179–83.
Vargas-Alarcon G, Posadas-Romero C, Posadas-Sanchez R, Martinez-Alvarado R, Gonzalez-Pacheco H, Martinez-Sanchez C, et al. The variant rs8048002 T > C in intron 3 of the MHC2TA gene is associated with risk of developing acute coronary syndrome. Cytokine. 2015;71:268–71.
Boullerne AI, Skias D, Hartman EM, Testai FD, Kalinin S, Polak PE, et al. A single-nucleotide polymorphism in serine-threonine kinase 11, the gene encoding liver kinase B1, is a risk factor for multiple sclerosis. ASN Neuro. 2015;7.
Schochet PZ. Technical methods report: Guidelines for multiple testing in impact evaluations (NCEE No, 2008–4018). National Center for Educational Evaluation and Regional Assistance, Institute of Education Sciences, U.S. Washington, DC: Department of Education; 2008.
Rausch SM, Gonzalez BD, Clark MM, Patten C, Felten S, Liu H, et al. SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors. Lung Cancer. 2012;77:217–23.
Mao JJ, Su HI, Feng R, Donelson ML, Aplenc R, Rebbeck TR, et al. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res. 2011;13:R8.
Garcia-Giralt N, Rodriguez-Sanz M, Prieto-Alhambra D, Servitja S, Torres-Del Pliego E, Balcells S, et al. Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study. Breast Cancer Res Treat. 2013;140:385–95.
Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol. 2010;28:4674–82.
Lotsch J, Klepstad P, Doehring A, Dale O. A GTP cyclohydrolase 1 genetic variant delays cancer pain. Pain. 2010;148:103–6.
Nissenbaum J, Devor M, Seltzer Z, Gebauer M, Michaelis M, Tal M, et al. Susceptibility to chronic pain following nerve injury is genetically affected by CACNG2. Genome Res. 2010;20:1180–90.
Sloan JA, de Andrade M, Decker P, Wampfler J, Oswold C, Clark M, et al. Genetic variations and patient-reported quality of life among patients with lung cancer. J Clin Oncol. 2012;30:1699–704.
Wang K, Demir IE, D’Haese JG, Tieftrunk E, Kujundzic K, Schorn S, et al. The neurotrophic factor neurturin contributes toward an aggressive cancer cell phenotype, neuropathic pain and neuronal plasticity in pancreatic cancer. Carcinogenesis. 2014;35:103–13.